Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics
2021 · Nature Medicine · 363 citations
https://doi.org/10.1038/s41591-020-01227-z
K
Ke Xu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
213
Papers
4.4K
Citations
31
h-index
57
i10-index
Ke Xu is an academic researcher from Shangrao Normal University. The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & Peroxisome Proliferator-Activated Receptors & Immune Cell Function and Interaction. The author has an h-index of 31, co-authored 182 publications.
ORCID: 0000-0003-2628-2061Papers by this author
worksExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
2021 · Communications Biology · 152 citations
https://doi.org/10.1038/s42003-021-02004-5
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
2015 · Cancer Cell · 151 citations
https://doi.org/10.1016/j.ccell.2015.06.006
The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction
2020 · Nature Communications · 81 citations
https://doi.org/10.1038/s41467-019-14082-5
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial
2022 · Nature Communications · 45 citations
https://doi.org/10.1038/s41467-022-31379-0
Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice
2023 · Cell Reports Medicine · 45 citations
https://doi.org/10.1016/j.xcrm.2023.100918
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat